SurModics and NuPathe partner on long-acting Parkinson’s treatment
SurModics Inc., a provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc., a neuroscience-focused specialty pharmaceutical company, announced in November that they signed a license agreement for NP201, the first long-acting treatment available in broadly acceptable dose form that maintains the potential to provide sustained relief from Parkinson’s disease without motor response complications.
EDEN PRAIRIE, Minn.—SurModics Inc., a provider of drug delivery andsurface modification technologies to the healthcare industry, and NuPathe Inc.,a neuroscience-focused specialty pharmaceutical company, announced in Novemberthat they signed a license agreement for NP201, the first long-acting treatmentavailable in broadly acceptable dose form that maintains the potential toprovide sustained relief from Parkinson's disease without motor responsecomplications. NP201 leverages NuPathe's long-acting delivery technology andSurModics' biodegradable polymer matrix implant technology to achieve optimaldrug release over an extended period of time. Under the licensing agreement,NuPathe will lead and fund development and commercialization. SurModics willprovide technical and manufacturing expertise and will be eligible to receivelicensing fees and milestone payments related to development of products forthe treatment of Parkinson's disease and other clinical indications. SurModicswill also receive royalties on product sales.
